Victory Pharma Completes Acquisition of Assets of MiddleBrook Pharmaceuticals

Company Expands Product Portfolio, Adds Drug Delivery Technology

05-Aug-2010 - USA

Victory Pharma, Inc. announced that it has completed the acquisition of substantially all of the assets of MiddleBrook Pharmaceuticals, Inc.

Through the acquisition, Victory Pharma has expanded its product portfolio with the addition of anti-infective products MOXATAG® and KEFLEX® as well as the PULSYS® drug delivery technology platform. The product additions complement Victory's current products, such as NAPRELAN®, which the company markets to primary care and specialist physicians.

"This acquisition reflects our strategy of leveraging our existing commercial infrastructure to expand our portfolio of marketed products," said Matt Heck, president and chief executive officer of Victory Pharma. "The addition of these products balances our portfolio nicely, as NAPRELAN's highest period of utilization is in the spring and summer, while MOXATAG's utilization peaks during the flu season. And we believe MOXATAG will substantially benefit from our management team's prior, successful experience marketing anti-infective products."

Other news from the department business & finance

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance